Abstract: This invention relates to a novel glycoprotein with anticoagulant activity in human urine, a process for its preparation and a pharmaceutical composition comprising the said glycoprotein for the prevention and/or treatment of diseases related to the disorders in the blood coagulation system.

Abstract: A method of producing a whey protein concentrate rich in immunoglobulins which comprises fractionating whey proteins into an immunoglobulin rich fraction and an immunoglobulin depleted fraction and concentrating at least the immunoglobulin rich fraction, in which either (i) a protein containing liquid selected from the group consisting of a whey, a liquid whey protein concentrate or a reconstituted whey protein concentrate powder is subjected to ultrafiltration through a membrane having a molecular weight cut-off of substantially 500,000 whereby to directly produce an immunoglobulin enriched concentrate together with fat, the permeate containing at least a major proportion of the remaining whey proteins, or (ii) a protein containing liquid selected from the group consisting of a whey, a liquid whey protein concentrate or a reconstituted whey protein concentrate powder is subjected to the action of an anion-exchange resin to produce an effluent, the whey proteins in which contain a higher proportion of immunog

Abstract: A method of removing an antigenic substance from a fluid comprises(1) forming a ternary complex by the interaction of(a) the antigenic substance,(b) a first antibody which contains a kappa chain and which binds to the antigenic substance, and(c) a second antibody which binds to the kappa chain of the first antibody, said second antibody being immobilized on a solid phase carrier, and(2) separating the fluid from the solid phase carrier.

Abstract: The invention provides a conjugate comprising FGF or other polypeptide reactive with an FGF receptor, and a cytotoxic agent. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, although other cytotoxic agents can also be advantageously used. The cytotoxic agent can be attached to FGF through a chemical bond or the composition can be prepared as a chimera, using techniques of recombinant DNA. The conjugate can be used to treat FGF-mediated pathophysiological conditions by specifically targeting cells having FGF receptors and inhibiting proliferation of or causing death of the cells. Additionally, the conjugate can be used to target cytotoxic agents into cells having FGF receptors, and to inhibit the proliferation of such cells. A method of purifying the conjugate on an immobilized heparin column is also provided.

Abstract: A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.

Abstract: The present invention relates to pharmaceutical combinations containing IFN.gamma. and at least one anthelminthic, and the use thereof for treating parasitoses in mammals or in humans.

Abstract: A multi-step process for purifying an immune serum globulin fraction from a crude plasma protein fraction involves precipitating non-serum globulin proteins from an aqueous suspension of the crude plasma protein fraction using a protein precipitant, adding a virus-inactivating agent to the clarified immune serum globulin-containing liquid, absorbing the immune serum globulins onto a cation exchange resin and washing non-serum globulin contaminants from the resin, subjecting the eluate to ultrafiltration to concentrate the immune serum globulins and separate them from low molecular weight species, contacting the concentrate with an anion exchange resin to absorb non-serum globulin contaminants, passing the imune-serum globulins through the anion exchange resin under conditions that leave non-serum globulin contaminants bound to the resin, and subjecting the filtrate to a molecular washing step to produce a purified immune serum globulin fraction.

Abstract: Two chitinases from Trichoderma harzianum P1 (ATCC 74058) show chitin-containing-fungus- and insect-inhibiting activity. The first is an endochitinase having a molecular weight of 36 kDa and an isoelectric point of 5.3.+-.0.2. The second is an exochitinase having a molecular weight of 36 kDa an an isoelectric point of 4.4.+-.0.2. The chitinases can be applied in contact with chitin-containing fungus or insect as an inhibitor thereof. The chitinases can be applied to plants or to soil around plants which need production from a chitinase-containing pest. The chitinases can also be used to isolate genes coding for them which can be inserted into a genome of a plant needing protection from a chitinase-containing pest or into the genome of a microorganism to provide transgenic microorganism useful to produce enzyme or as a biocontrol agent.

Abstract: A modified pertussis toxin suitable as a pertussis vaccine having an essentially unmodified B-oligomer and a catalytic subunit which is inactivated by treatment with polyphosphate compounds, sulfhydryl reductants and mild detergents followed by modification of the activated --SH groups to inhibit ADP-ribosylating activity.

Abstract: A process for recovering highly pure, recombinant IL-2 from transformed microorganisms in which the cells are disrupted; impure recombinant IL-2 is isolated in the form of refractile bodies from the disruptate; the impure IL-2 is dissolved and denatured with at least 6M guanidine hydrochloride containing a reducing agent; the reduced IL-2 is precipitated and resolubilized; the reduced solubilized IL-2 therein is oxidized by a controlled oxidation; the oxidized IL-2 is refolded by reducing the concentration of guanidine hydrochloride in the solution; and the oxidized, refolded IL-2 is further purified by ion exchange chromatography or hydrophobic interaction chromatography and ion exchange chromatography.

Abstract: The invention relaates to the production of collagen fibers by comminuting collagen containing tissues, drying the comminuted product and milling the dried material while maintaining the temperature sufficiently low to prevent substantial conversion of collagen to gelatin. The collagen fiber product is particularly useful for restructuring poorly textured meats, mechanically recovered meat products, offal, fish, fish products and other protein products to improve textural properties, water retention, fat retention, eating quality, juicines, succulence, shape, size retention and protein content.

Abstract: Conjugates of trichothecenes and agents that bind to a defined population of cells are disclosed. Preferred are conjugates of trichothecene molecules with polyclonal or monoclonal antibodies or fragments thereof that recognize antigens that are present only on tumor cells or are augmented in their expression on tumor cells as compared to normal tissues. Trichothecene molecules are coupled to the agent through non-covalent and covalent linkages, such as peptide bonds, disulfide bonds, thioester bonds, or thioether bonds. A method for inhibiting the growth and metabolism of antigen-positive cells is also disclosed.

Abstract: Alcohol is suitable for the extraction of salt from biomass-containing suspensions, in particular from the salt-containing lower phase of an aqueous 2-phase extraction of intracellular proteins after cell disruption, with the formation of a salt-containing alcoholic upper phase. It is possible to use ethanol, propanol, isopropanol or tert.-butanol, but especially ethanol, as the alcohol. The upper phase is separated from the lower phase by disk separators or decanters. The extraction is carried out, in particular, as a countercurrent extraction in at least three stages, and uses 10 to 30% by weight salt-containing suspension or liquid with 30 to 50% by weight alcohol, in particular ethanol, remainder water. The alcohol is removed from the resulting salt-rich upper phase by evaporation, and the salt solution is recycled where appropriate after further concentration to obtain proteins.

Abstract: Binary polymer mixtures of albumin and glycosaminoglycan and ternary polymer mixtures of polyionic polypeptide and high molecular weight and highly charged polyanions are useful for managing skin including wrinkles or other irregularities. Aqueous compositions of the ternary mixtures have pH dependent phase change properties and provide skin activated films.

Abstract: A method of crosslinking protein comprises making a composition which comprises a protein, a sugar, a water-soluble salt of a carboxylic acid, water, and an additional ingredient which is to be encapsulated or entrapped within the crosslinked protein matrix. The composition is thereafter heated while maintaining the moisture content at a level of at least about 3 weight percent, based on the weight of the composition.A product comprises a protein which is crosslinked to degree at which it is substantially insoluble upon being placed in water at 100.degree. C. for at least 3 minutes, a sugar, a water-soluble salt of a carboxylic acid, water, and an additional ingredient which is encapsulated or entrapped within the crosslinked protein matrix.

Abstract: The chlorohydrin content of a liquid containing hydrolyzed protein obtained by hydrolysis of protein with hydrochloric acid is reduced in an apparatus system by introducing alkali into the liquid flowing under pressure in a piping system to increase the pH of the liquid, after which the pH-increased flowing liquid is heated, and then the heated flowing liquid is held for a time sufficient in a holding piping section to reduce the chlorohydrin content of the hydrolyzed protein contained in the liquid. The flowing liquid under pressure then is cooled before or after addition of hydrochloric acid which is employed to adjust the pH of the liquid.

Abstract: An improved method for the purification of monoclonal antibodies using Protein G, whereby the monoclonal antibodies are eluted from the Protein G at alkaline pH.

Abstract: A process for solubilizing membrane receptor proteins which includes exposing an outer membrane having the desired protein to an oxidizing agent, treating the membrane with a detergent and treating with an inhibitory material lowering agent. This method maintains the activity of the membrane proteins after solubilization.

Abstract: A method of fractionating plasma protein which comprises treating a plasma protein-containing material in the following sequence of steps, provided that steps (ii) through (v) may be performed in an optional order: (i) freeze-thaw treatment, (ii) treatment at 5 to 10% ethanol concentration, (iii) treatment with an anion exchanger, (iv) affinity chromatography with immobilized lysine, (v) affinity chromatography with immobilized heparin, (vi) treatment at 18 to 30% ethanol concentration, (vii) treatment at 35 to 45% ethanol concentration.

Abstract: This invention relates to a method of isolating and purifying proteins such as fibroblast growth factor using metal chelate affinity column chromatography and without the use of heparin. Also disclosed is a method of recovering bFGF multimers and purifying bFGF using metal chelate affinity column chromatography in the absence of heparin.